Literature DB >> 14763236

Clonazepam in the pharmacological treatment of vertigo and tinnitus.

Mauricio Malavasi Ganança1, Heloisa Helena Caovilla, Fernando Freitas Ganança, Cristina Freitas Ganança, Mário Sérgio Lei Munhoz, Maria Leonor Garcia da Silva, Flávio Serafini.   

Abstract

We carried out a retrospective survey of 25 years of clinical experience with the use of clonazepam as a vestibular and tinnitus suppressant in the pharmacological treatment of vestibular or cochleovestibular disorders due to different causes. We reviewed the medical records of 3,357 outpatients treated with a 0.5 or 1.0-mg daily dosage of oral clonazepam during 60-180 days. Complete or substantial control of vertigo or nonvertiginous dizziness was achieved in 77.4% of the vertigo patients. Tinnitus was improved in 32.0% of the tinnitus patients. Light or mild drowsiness, depression, nightmares, or lowering of libido, reported by 16.9% of the patients as adverse side effects, tended to subside with continued therapy. We concluded that clonazepam is a very useful and safe drug for the symptomatic treatment of patients suffering from cochleovestibular disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14763236

Source DB:  PubMed          Journal:  Int Tinnitus J        ISSN: 0946-5448


  14 in total

1.  [Decompensated chronic tinnitus and high-dose benzodiazepine dependence. Between Scylla and Charybdis].

Authors:  U Bonnet
Journal:  Nervenarzt       Date:  2014-07       Impact factor: 1.214

2.  Dose-dependent attenuation of auditory phantom perception (tinnitus) by PET-guided repetitive transcranial magnetic stimulation.

Authors:  Christian Plewnia; Matthias Reimold; Arif Najib; Bernhard Brehm; Gerald Reischl; Stefan K Plontke; Christian Gerloff
Journal:  Hum Brain Mapp       Date:  2007-03       Impact factor: 5.038

3.  PHARMACOLOGICAL TREATMENTS FOR TINNITUS: NEW AND OLD.

Authors:  R Salvi; E Lobarinas; W Sun
Journal:  Drugs Future       Date:  2009       Impact factor: 0.148

4.  Non-penetrating round window electrode stimulation for tinnitus therapy followed by cochlear implantation.

Authors:  Gentiana I Wenzel; Petra Sarnes; Athanasia Warnecke; Timo Stöver; Burkard Jäger; Anke Lesinski-Schiedat; Thomas Lenarz
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-12-06       Impact factor: 2.503

5.  Tinnitus psychopharmacology: A comprehensive review of its pathomechanisms and management.

Authors:  Michele Fornaro; Matteo Martino
Journal:  Neuropsychiatr Dis Treat       Date:  2010-06-24       Impact factor: 2.570

Review 6.  Emerging pharmacotherapy of tinnitus.

Authors:  Berthold Langguth; Richard Salvi; Ana Belén Elgoyhen
Journal:  Expert Opin Emerg Drugs       Date:  2009-12       Impact factor: 4.191

Review 7.  [The role of cochlear neurotransmitters in tinnitus].

Authors:  B Mazurek; T Stöver; H Haupt; J Gross; A Szczepek
Journal:  HNO       Date:  2007-12       Impact factor: 1.284

8.  Role of acamprosate in sensorineural tinnitus.

Authors:  Dinesh Kumar Sharma; Sharanjit Kaur; Jatinder Singh; Inderpal Kaur
Journal:  Indian J Pharmacol       Date:  2012-01       Impact factor: 1.200

9.  Tinnitus: network pathophysiology-network pharmacology.

Authors:  Ana B Elgoyhen; Berthold Langguth; Sven Vanneste; Dirk De Ridder
Journal:  Front Syst Neurosci       Date:  2012-01-25

Review 10.  Nimodipine in otolaryngology: from past evidence to clinical perspectives.

Authors:  D Monzani; E Genovese; L A Pini; F Di Berardino; M Alicandri Ciufelli; G M Galeazzi; L Presutti
Journal:  Acta Otorhinolaryngol Ital       Date:  2015-06       Impact factor: 2.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.